Matching articles for "Lamisil"
Treatment of Onychomycosis
The Medical Letter on Drugs and Therapeutics • October 18, 2021; (Issue 1635)
Onychomycosis is caused most commonly by
Trichophyton rubrum or T. mentagrophytes. About
10% of all persons worldwide and 40% of those ≥60
years old are believed to have the disease. Risk
factors include...
Onychomycosis is caused most commonly by
Trichophyton rubrum or T. mentagrophytes. About
10% of all persons worldwide and 40% of those ≥60
years old are believed to have the disease. Risk
factors include older age, diabetes, poor peripheral
circulation, smoking, HIV infection, psoriasis, and
immunosuppression. Left untreated, onychomycosis
can cause nail plate destruction, ingrown nails, and
(particularly in patients with diabetes) secondary
infections. Guidelines on treatment of onychomycosis
have been published.
Tavaborole Topical Solution (Kerydin) for Onychomycosis
The Medical Letter on Drugs and Therapeutics • March 2, 2015; (Issue 1463)
The FDA has approved tavaborole 5% solution
(Kerydin – Anacor Pharmaceuticals) for topical treatment
of toenail onychomycosis due to Trichophyton
rubrum or Trichophyton mentagrophytes. It is the
first...
The FDA has approved tavaborole 5% solution
(Kerydin – Anacor Pharmaceuticals) for topical treatment
of toenail onychomycosis due to Trichophyton
rubrum or Trichophyton mentagrophytes. It is the
first oxaborole antifungal drug to be approved for this
indication.
Efinaconazole Topical Solution (Jublia) for Onychomycosis
The Medical Letter on Drugs and Therapeutics • September 15, 2014; (Issue 1451)
The FDA has approved efinaconazole 10% solution
(Jublia – Valeant) for topical treatment of toenail
onychomycosis due to Trichophyton rubrum and/or
Trichophyton mentagrophytes. It is the first...
The FDA has approved efinaconazole 10% solution
(Jublia – Valeant) for topical treatment of toenail
onychomycosis due to Trichophyton rubrum and/or
Trichophyton mentagrophytes. It is the first topical
triazole antifungal drug to be approved for this
indication. A topical oxaborole antifungal solution,
tavaborole 5% (Kerydin – Anacor), also recently
approved by the FDA for the same indication will be
reviewed in a future issue.
Luliconazole Cream (Luzu) for Tinea Infections
The Medical Letter on Drugs and Therapeutics • June 23, 2014; (Issue 1445)
The FDA has approved luliconazole (Luzu Cream, 1% –
Valeant) for treatment of tinea pedis, tinea cruris, and
tinea corporis...
The FDA has approved luliconazole (Luzu Cream, 1% –
Valeant) for treatment of tinea pedis, tinea cruris, and
tinea corporis infections.
Antifungal Drugs
The Medical Letter on Drugs and Therapeutics • August 1, 2012; (Issue 120)
The drugs of choice for treatment of fungal infections
are listed in the table that begins on page 62. Some of
the indications and dosages recommended here have
not been approved by the FDA. More detailed...
The drugs of choice for treatment of fungal infections
are listed in the table that begins on page 62. Some of
the indications and dosages recommended here have
not been approved by the FDA. More detailed guidelines
for some of these infections are available online
from the Infectious Diseases Society of America
(www.idsociety.org).
Antifungal Drugs
The Medical Letter on Drugs and Therapeutics • December 1, 2009; (Issue 88)
The drugs of choice for treatment of some fungal infections are listed. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines are available online from...
The drugs of choice for treatment of some fungal infections are listed. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines are available online from the Infectious Diseases Society of America (www.idsociety.org).
In Brief: Tamoxifen and SSRI Interactions
The Medical Letter on Drugs and Therapeutics • June 15, 2009; (Issue 1314)
Use of a selective serotonin reuptake inhibitor (SSRI) is common in women taking tamoxifen (Nolvadex, and others) for breast cancer, both to treat depression and to decrease hot flashes. However, tamoxifen must...
Use of a selective serotonin reuptake inhibitor (SSRI) is common in women taking tamoxifen (Nolvadex, and others) for breast cancer, both to treat depression and to decrease hot flashes. However, tamoxifen must be metabolized by CYP2D6 to become pharmacologically fully active (MJ Higgins et al. J Natl Compr Canc Netw 2009; 7:203), and the SSRIs fluoxetine (Prozac, and others) and paroxetine (Paxil, and others) are strong inhibitors of CYP2D6. Sertraline (Zoloft, and others) inhibits CYP2D6 to a lesser extent. Citalopram (Celexa, and others) and escitalopram (Lexapro), the 2 other SSRIs approved for treatment of depression, are only weak inhibitors of CYP2D6.
Two observational studies presented at a recent meeting of the American Society of Clinical Oncology (45th annual meeting, May 29-June 2, 2009, Orlando, FL abstracts CRA508, CRA509) examined the effect of strong inhibitors of CYP2D6 on the success rate of tamoxifen in preventing recurrence of breast cancer. One found that women who took fluoxetine, paroxetine or sertraline (or bupropion, duloxetine, terbinafine, quinidine or long-term diphenhydramine) with tamoxifen had a higher 2-year recurrence rate (13.9% vs. 7.5%). The other study found no association between cancer recurrence and use of a CYP2D6 inhibitor.
There is no good evidence that any one SSRI is more effective than any other for treatment of depression. For women who are taking tamoxifen and need to begin treatment with an SSRI to treat depression, citalopram or escitalopram might be the safest choice (Treat Guidel Med Lett 2006; 4:35). Use of an SSRI to treat hot flashes in women taking tamoxifen should probably be reconsidered.
Download: U.S. English
Two observational studies presented at a recent meeting of the American Society of Clinical Oncology (45th annual meeting, May 29-June 2, 2009, Orlando, FL abstracts CRA508, CRA509) examined the effect of strong inhibitors of CYP2D6 on the success rate of tamoxifen in preventing recurrence of breast cancer. One found that women who took fluoxetine, paroxetine or sertraline (or bupropion, duloxetine, terbinafine, quinidine or long-term diphenhydramine) with tamoxifen had a higher 2-year recurrence rate (13.9% vs. 7.5%). The other study found no association between cancer recurrence and use of a CYP2D6 inhibitor.
There is no good evidence that any one SSRI is more effective than any other for treatment of depression. For women who are taking tamoxifen and need to begin treatment with an SSRI to treat depression, citalopram or escitalopram might be the safest choice (Treat Guidel Med Lett 2006; 4:35). Use of an SSRI to treat hot flashes in women taking tamoxifen should probably be reconsidered.
Download: U.S. English
Antifungal Drugs
The Medical Letter on Drugs and Therapeutics • January 1, 2008; (Issue 65)
The drugs of choice for treatment of some fungal infections are listed in the tables. Some of the indications and dosages recommended here have not been approved by the FDA. Other guidelines are available from...
The drugs of choice for treatment of some fungal infections are listed in the tables. Some of the indications and dosages recommended here have not been approved by the FDA. Other guidelines are available from the Infectious Diseases Society of America (www.idsociety.org).
Antifungal Drugs
The Medical Letter on Drugs and Therapeutics • February 1, 2005; (Issue 30)
The drugs of choice for treatment of some fungal infections are listed in the table that begins on page 8. Some of the indications and dosages recommended here have not been approved by the...
The drugs of choice for treatment of some fungal infections are listed in the table that begins on page 8. Some of the indications and dosages recommended here have not been approved by the FDA.
Topical Butenafine for Tinea Pedis
The Medical Letter on Drugs and Therapeutics • July 4, 1997; (Issue 1004)
Butenafine hydrochloride 1% cream (Mentax - Penederm), a benzylamine antifungal drug similar to the allylamines terbinafine (Lamisil) and naftifine (Naftin), is now available in the USA for topical treatment...
Butenafine hydrochloride 1% cream (Mentax - Penederm), a benzylamine antifungal drug similar to the allylamines terbinafine (Lamisil) and naftifine (Naftin), is now available in the USA for topical treatment of tinea pedis, tinea corporis and tinea cruris.
Terbinafine for Onychomycosis
The Medical Letter on Drugs and Therapeutics • August 16, 1996; (Issue 981)
Terbinafine (Lamisil - Sandoz), an allylamine synthetic antifungal, previously available in the USA in a topical formulation (Medical Letter, 35:76, 1993) has now been marketed for oral use in the treatment...
Terbinafine (Lamisil - Sandoz), an allylamine synthetic antifungal, previously available in the USA in a topical formulation (Medical Letter, 35:76, 1993) has now been marketed for oral use in the treatment of fungal nail infections caused by dermatophytes. Oral terbinafine has been available in Europe since 1992.
Itraconazole for Onychomycosis
The Medical Letter on Drugs and Therapeutics • January 19, 1996; (Issue 966)
Itraconazole (Sporanox - Janssen), an oral antifungal triazole that has been available in the USA since 1992 for treatment of deep fungal infections (Medical Letter, 35:7, 1993), is now being marketed for...
Itraconazole (Sporanox - Janssen), an oral antifungal triazole that has been available in the USA since 1992 for treatment of deep fungal infections (Medical Letter, 35:7, 1993), is now being marketed for treatment of dermatophyte infections of the toenails, with or without fingernail involvement.
Topical Terbinafine for Tinea Infections
The Medical Letter on Drugs and Therapeutics • August 20, 1993; (Issue 903)
Terbinafine 1% cream (Lamisil - Sandoz), an allylamine synthetic antifungal drug chemically related to naftifine (Naftin - Medical Letter, 30:98, 1988), is now available in the USA for topical treatment of...
Terbinafine 1% cream (Lamisil - Sandoz), an allylamine synthetic antifungal drug chemically related to naftifine (Naftin - Medical Letter, 30:98, 1988), is now available in the USA for topical treatment of tinea pedis, tinea cruris, and tinea corporis infections. An oral formulation is available in Europe and is under investigation here.